Abstract | BACKGROUND: OBJECTIVE: DESIGN: Randomized, double-blind, placebo-controlled trial, SETTING: Clinical Research Center, National Institutes of Health. PATIENTS: INTERVENTION: Placebo or POF (1200-2000 mg/day) for 10 months, as prednisone was tapered. MEASUREMENTS: Primary endpoints: sustained improvement in two or more pulmonary function parameters, or a combination of one pulmonary function parameter and dyspnea. RESULTS: Except for one patient, primary endpoints were not reached in POF-treated patients. Therefore, a post hoc analysis was performed. The observed relative risk reduction for flares associated with POF treatment was 54.9% (95% CI 0.21, 0.89) and the absolute risk reduction was 50.6% (95% CI 0.22, 0.80). Compared to placebo treatment, in the POF group, the mean prednisone dose was lower at 8 and 10 months (p = 0.007 and 0.01 respectively), and there was a trend towards less prednisone usage over the entire study period (p = 0.053), as determined by cumulative change analysis. CONCLUSIONS: Although our exploratory post hoc analysis suggested that POF reduced flares and had steroid-sparing effects, given the study limitations, definitive conclusions cannot be drawn regarding the efficacy of POF in pulmonary sarcoidosis. In addition, gastrointestinal side-effects, at the doses used, would seem to limit the use of POF in treating pulmonary sarcoidosis. Overall, however, this trial may provide a basis for using more specific, better-tolerated, PDE inhibitors in future clinical trials.
|
Authors | M K Park, Fontana Jr, H Babaali, L I Gilbert-McClain, M Stylianou, J Joo, J Moss, V C Manganiello |
Journal | Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
(Sarcoidosis Vasc Diffuse Lung Dis)
Vol. 26
Issue 2
Pg. 121-31
(Jul 2009)
ISSN: 1124-0490 [Print] Italy |
PMID | 20560292
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Intramural)
|
Chemical References |
- Phosphodiesterase Inhibitors
- Pentoxifylline
|
Topics |
- Adolescent
- Adult
- Aged
- Biopsy
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Forced Expiratory Flow Rates
(drug effects)
- Humans
- Hypertension, Pulmonary
(drug therapy, pathology, physiopathology)
- Male
- Middle Aged
- Pentoxifylline
(administration & dosage, therapeutic use)
- Phosphodiesterase Inhibitors
(administration & dosage, therapeutic use)
- Respiratory Function Tests
- Treatment Outcome
- Young Adult
|